N@N

Skyepharma PLC: Skyepharma PLC announces Board Appointment

^{Published on 2009-05-14 23:34:39, Last Modified on 2009-11-02 12:09:57 - Market Wire}
 

London, UK--(Marketwire - May 15, 2009) -

 Appointment of New Non-Executive Director LONDON, UK, 15 May, 2009 - SkyePharma PLC (LSE: SKP) today announces that it will appoint a new Non-Executive Director, Dr Thomas Werner, to the Board with effect from 16 May 2009. Dr Werner, 52, is a senior-level pharmaceutical executive with over 26 years experience in the pharmaceutical industry, most recently as Managing Director and Senior Vice-President of GlaxoSmithKline Germany. Prior to that, he held senior positions at GlaxoWellcome Germany, Bristol-Myers Squibb Germany and Convatec Germany, (a medical devices subsidiary of Bristol Myers Squibb). Dr Werner sits on the Board of Trustees of both the Paul Ehrlich Association and the Robert Koch Foundation. No disclosures are required under section 9.6.13 of the Listing Rules. As previously announced Dr Argeris (Jerry) Karabelas will stand down from the Board at the conclusion of the Annual General Meeting taking place later today. Jeremy Scudamore, Non-Executive Chairman of SkyePharma, said: "On behalf of the Board and staff, I would like to reiterate my thanks to Jerry for the tremendous contribution he has made to the Company over the past eight years and to welcome Thomas to the Board of SkyePharma. His experience as a senior international manager in the pharmaceutical industry will enable him to be of significant value to SkyePharma as it moves forward." For further information please contact: SkyePharma PLC Ken Cunningham +44 20 7491 1777 Peter Grant Financial Dynamics Jonathan Birt +44 20 7831 3113 Susan Quigley About SkyePharma PLC Using its proprietary drug delivery technologies, SkyePharma develops new formulations of existing products to provide a clinical advantage and life-cycle extension. The Group has twelve approved products in the areas of oral, inhalation and topical delivery. The Group's products are marketed throughout the world by leading pharmaceutical companies. For more information, visit [ www.skyepharma.com ]. This information is provided by RNS The company news service from the London Stock Exchange END